StreetInsider.com News Articles

PMGC Holdings secures royalty payment plan from Elevai Skincare sale

Fri, 18 Sep 2026 08:01:57 -0400

PMGC Holdings Inc. (NASDAQ: ELAB) announced it has entered into a payment agreement with Longevity Health Holdings, Inc. to structure royalty payments owed from the January 2025 sale of its Elevai Skincare business.

Under the agreement, Longevity has acknowledged a 2025 royalty obligation of $94,937, with interest accruing at the Wall Street Journal Prime Rate plus 1.00% per annum from the original April 2026 due date. Monthly installments of $10,000 will begin October 15, 2026, with all amounts due no later than August 28, 2031.

The payment plan stems from an asset purchase agreement dated December 31, 2024, in which PMGC negotiated

Form 8-K PMGC Holdings Inc. For: Sep 18

Fri, 18 Sep 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260918/27078365.html

PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings

Fri, 18 Sep 2026 08:00:00 -0400

Binding, interest-bearing payment plan converts PMGC’s 5% net sales royalty into scheduled monthly cash payments to NorthStrive Biosciences through August 2031, creating recurring, non-dilutive cash flow
Agreement covers the 2025 royalty and all future royalty and earnout payments, backed by joint and several obligors, mandatory prepayments tied to Longevity capital events, and annual audit rights

NEWPORT BEACH, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (“PMGC” or the “Company”) (Nasdaq: ELAB), a diversified holding company, today announced that the Company and its wholly owned subsidiary, NorthStrive Biosciences Inc.

PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings

Fri, 18 Sep 2026 08:00:00 -0400

Binding, interest-bearing payment plan converts PMGC’s 5% net sales royalty into scheduled monthly cash payments to NorthStrive Biosciences through August 2031, creating recurring, non-dilutive cash flow
Agreement covers the 2025 royalty and all future royalty and earnout payments, backed by joint and several obligors, mandatory prepayments tied to Longevity capital events, and annual audit rights

NorthStrive expands drug discovery deal with Yuva Biosciences

Tue, 01 Sep 2026 07:49:57 -0400

NorthStrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), has executed a First Amendment to its Development and License Agreement with Yuva Biosciences, Inc., launching a structured three-phase Expansion Program to advance four AI-discovered compounds toward lead compound nomination for cardiac disease and obesity applications.

The Expansion Program builds on Phase III results announced July 1, 2026, in which four small-molecule candidates selected by Yuva Biosciences' MitoNova AI platform showed statistically significant increases in ANT1, a mitochondrial protein involved in skeletal muscle energy metabolism, in primary human skeletal muscle cells. The program is expected to take approximately six months.

The

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Th

Tue, 01 Sep 2026 07:45:00 -0400

Building on positive Phase III results from the parties' AI-driven drug discovery program, the six-month Expansion Program will narrow the four validated compounds toward a nominated lead and designated backup.

The Amendment also strengthens the exclusive Cardiac Disease and Obesity field of use and adds a right of first refusal across the broader cardiometabolic field.

NEWPORT BEACH, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) ("PMGC" or the "Company"), today announced the execution of a First Amendment to its Development and License Agreement (the

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Th

Tue, 01 Sep 2026 07:45:00 -0400

The Amendment also strengthens the exclusive Cardiac Disease and Obesity field of use and adds a right of first refusal across the broader cardiometabolic field.

Form 8-K PMGC Holdings Inc. For: Aug 21

Thu, 27 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260827/26991350.html

Form 8-K PMGC Holdings Inc. For: Aug 21

Thu, 27 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260827/26991350.html

PMGC Holdings drops Arizona acquisition after due diligence review

Wed, 26 Aug 2026 08:18:45 -0400

PMGC Holdings Inc. (Nasdaq: ELAB) has terminated a non-binding letter of intent to acquire a 76% controlling interest in an Arizona-based precision machining and contract manufacturing company, citing unfavorable historical financial results uncovered during audit-stage due diligence.

The LOI, announced June 1, 2026, had contemplated an all-cash acquisition based on unaudited figures showing the target generated approximately $5.46 million in revenue and approximately $1.05 million in EBITDA for fiscal year 2025. After completing a GAAP audit process, PMGC determined the target's historical financial profile was less favorable than initially anticipated and that the total cost of the transaction no longer met

PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfol